Literature DB >> 29618660

Transcriptomics and machine learning predict diagnosis and severity of growth hormone deficiency.

Philip G Murray1,2, Adam Stevens1, Chiara De Leonibus1, Ekaterina Koledova3, Pierre Chatelain4, Peter E Clayton1,2.   

Abstract

BACKGROUND: The effect of gene expression data on diagnosis remains limited. Here, we show how diagnosis and classification of growth hormone deficiency (GHD) can be achieved from a single blood sample using a combination of transcriptomics and random forest analysis.
METHODS: Prepubertal treatment-naive children with GHD (n = 98) were enrolled from the PREDICT study, and controls (n = 26) were acquired from online data sets. Whole blood gene expression was correlated with peak growth hormone (GH) using rank regression and a random forest algorithm tested for prediction of the presence of GHD and in classification of GHD as severe (peak GH <4 μg/l) and nonsevere (peak ≥4 μg/l). Performance was assessed using area under the receiver operating characteristic curve (AUC-ROC).
RESULTS: Rank regression identified 347 probe sets in which gene expression correlated with peak GH concentrations (r = ± 0.28, P < 0.01). These 347 probe sets yielded an AUC-ROC of 0.95 for prediction of GHD status versus controls and an AUC-ROC of 0.93 for prediction of GHD severity.
CONCLUSION: This study demonstrates highly accurate diagnosis and disease classification for GHD using a combination of transcriptomics and random forest analysis. TRIAL REGISTRATION: NCT00256126 and NCT00699855. FUNDING: Merck and the National Institute for Health Research (CL-2012-06-005).

Entities:  

Keywords:  Endocrinology; growth factors

Mesh:

Substances:

Year:  2018        PMID: 29618660      PMCID: PMC5928867          DOI: 10.1172/jci.insight.93247

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  56 in total

1.  Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  A Custom Targeted Next-Generation Sequencing Gene Panel for the Diagnosis of Genetic Nephropathies.

Authors:  Christopher P Larsen; Tim Durfee; Jon D Wilson; Marjorie L Beggs
Journal:  Am J Kidney Dis       Date:  2016-01-12       Impact factor: 8.860

3.  Growth and growth hormone. I. Changes in serum level of growth hormone following hypoglycemia in 134 children with growth retardation.

Authors:  S L Kaplan; C A Abrams; J J Bell; F A Conte; M M Grumbach
Journal:  Pediatr Res       Date:  1968-01       Impact factor: 3.756

4.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

Review 5.  Hormonal control of programmed cell death/apoptosis.

Authors:  W Kiess; B Gallaher
Journal:  Eur J Endocrinol       Date:  1998-05       Impact factor: 6.664

6.  A comparative study of cancer proteins in the human protein-protein interaction network.

Authors:  Jingchun Sun; Zhongming Zhao
Journal:  BMC Genomics       Date:  2010-12-01       Impact factor: 3.969

7.  Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass.

Authors:  P M Martha; K M Gorman; R M Blizzard; A D Rogol; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  1992-02       Impact factor: 5.958

8.  Cytoscape 2.8: new features for data integration and network visualization.

Authors:  Michael E Smoot; Keiichiro Ono; Johannes Ruscheinski; Peng-Liang Wang; Trey Ideker
Journal:  Bioinformatics       Date:  2010-12-12       Impact factor: 6.937

9.  The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics.

Authors:  Haiyuan Yu; Philip M Kim; Emmett Sprecher; Valery Trifonov; Mark Gerstein
Journal:  PLoS Comput Biol       Date:  2007-02-14       Impact factor: 4.475

10.  Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

Authors:  A Stevens; P Clayton; L Tatò; H W Yoo; M D Rodriguez-Arnao; J Skorodok; G R Ambler; M Zignani; J Zieschang; G Della Corte; B Destenaves; A Champigneulle; J Raelson; P Chatelain
Journal:  Pharmacogenomics J       Date:  2013-04-09       Impact factor: 3.550

View more
  5 in total

1.  Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency.

Authors:  George M Bright; Minh-Ha T Do; John C McKew; Werner F Blum; Michael O Thorner
Journal:  J Endocr Soc       Date:  2021-02-25

2.  A systematic review on machine learning in sellar region diseases: quality and reporting items.

Authors:  Nidan Qiao
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 3.  Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature.

Authors:  Adam Stevens; Reena Perchard; Terence Garner; Peter Clayton; Philip Murray
Journal:  Rev Endocr Metab Disord       Date:  2021-03-12       Impact factor: 6.514

4.  A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI.

Authors:  Taeyoun Lee; Kyungchul Song; Beomseok Sohn; Jihwan Eom; Sung Soo Ahn; Ho-Seong Kim; Seung-Koo Lee
Journal:  Yonsei Med J       Date:  2022-09       Impact factor: 3.052

5.  Gene expression signatures predict response to therapy with growth hormone.

Authors:  Adam Stevens; Philip Murray; Chiara De Leonibus; Terence Garner; Ekaterina Koledova; Geoffrey Ambler; Klaus Kapelari; Gerhard Binder; Mohamad Maghnie; Stefano Zucchini; Elena Bashnina; Julia Skorodok; Diego Yeste; Alicia Belgorosky; Juan-Pedro Lopez Siguero; Regis Coutant; Eirik Vangsøy-Hansen; Lars Hagenäs; Jovanna Dahlgren; Cheri Deal; Pierre Chatelain; Peter Clayton
Journal:  Pharmacogenomics J       Date:  2021-05-27       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.